Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse

This study has been terminated.
(The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the first two years of patients enrolment)
Sponsor:
Information provided by (Responsible Party):
Hellenic Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT00926107
First received: June 22, 2009
Last updated: November 9, 2011
Last verified: November 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2011
  Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)